NEWS
Beckman Coulter Diagnostics invests €10m in Ireland
Beckman Coulter Diagnostics has announced a €10 million investment for its manufacturing and research base in County Clare, Ireland, that underscores its commitment to innovation and growth in the region.
The investment will enhance Beckman
Coulter’s production with the addition of two new fully automated reagent filling lines and upgrades to the site’s infrastructure, boosting both efficiency and capacity.
The company is actively hiring for
50 open roles and also announced 30 additional jobs arising, to be recruited between 2025 and 2027 for highly skilled professionals at its Co. Clare facility for key functions such as production operations, quality and regulatory affairs, research and development, and more.
A special event at Beckman Coulter’s high-tech site at O´Callaghan´s Mills, Co. Clare was attended by Beckman Coulter’s Ireland-born president Kevin O’Reilly, who was appointed earlier this year to lead the company and its 11,000 employees globally. Others in attendance included European Commissioner-designate Michael McGrath, as well as other national and local public representatives and industry stakeholders. Kevin O’Reilly is pictured far left, with (left-right): Mary Buckley, Executive Director of foreign direct investment agency IDA Ireland; Michael McGrath; and Orlaith Lawler, Beckman Coulter Diagnostics’ VP of Operations EMEAI. Beckman Coulter’s economic contribution is highly significant to East Clare and the wider Mid-West region thanks to the 560 jobs it provides in its facility. Employment at the site is anticipated to rise to over 600 jobs, with headcount figures having almost doubled since 2018.
Sir Patrick Vallance appointed Minister for Science
The new Labour Government has appointed Sir Patrick Vallance FRS FMedSci FRCP HonFREng as Minister of State (Minister for Science). He was previously Government Chief Scientific Adviser (GCSA) from April 2018 to April 2023. Vallance (pictured) was also National Technology Adviser (NTA) and Head of the Government Science and Engineering (GSE) Profession. Previously he was President, R&D at GlaxoSmithKline (GSK) from 2012 until 2017, having joined the company in 2006. Prior to joining GSK, he was a clinical academic, Professor of Medicine and led the Division of Medicine at UCL. He has many years’ experience of basic science and clinical research, and was a consultant physician in the NHS.
His research spanned work on medicinal chemistry and structural biology, through to cellular work, studies in humans and use of large electronic health record databases. He was elected to the Academy of Medical Sciences in 1999 and to the Royal Society in 2017. He was on the Board of the UK Office for Strategic Co-ordination of
Health Research (OSCHR) from 2009 to 2016. He is an Honorary Fellow at UCL and holds honorary degrees from Imperial College London, Glasgow University, University of York, and St George’s, University of London. He was a non- executive director and board member for UK Biobank and a non-executive board member for Genome Research but stepped down in taking up the GCSA role.
Philips IntelliSite Pathology Solution receives 510(k) clearance
Philips IntelliSite Pathology Solution 5.1 has received 510(k) clearance from the US Food and Drug Administration. Philips was first to market an FDA-approved digital pathology solution in 2017 and is the most widely deployed digital pathology solution for primary diagnosis around the world. The solution supports remote collaboration, and promotes teamwork, aiding diagnosis, boosting productivity, addressing staff shortages, and cutting costs. Philips IntelliSite Pathology Solution, is comprehensive and scalable, integrating hardware, software, storage, analysis, and enterprise-wide connectivity, providing pathologists with fully integrated, end- to-end digital workflows. This seamless integration helps pathologists deliver accurate diagnoses, ultimately improving patient outcomes. Philips has already helped over 300 pathology laboratories implement digital pathology, helping pathologists to save time and collaborate virtually to deliver high-quality pathology reports and interact with other specialists in a patient’s multi- disciplinary care team. Philips’ digital pathology solution includes whole-slide scanners, image management system,
10
and proven implementation and support services to guide the transformation from analogue to fully digital pathology workflows.
“Digital pathology is helping to
revolutionise how we diagnose and potentially treat cancer. With the 510(k) approval we expand our ability to help pathology laboratories transform to fully digital workflows, saving time and easing the burden on pathologists and patients,” said Martijn Hartjes, Clinical Informatics Business Leader at Philips. “We are advancing the digital transformation in pathology and multi-disciplinary clinical collaboration between pathologists, radiologists, oncologists, and other healthcare professionals, empowering clinicians with the tools they need to deliver improved patient outcomes and care.”
AUGUST 2024
WWW.PATHOLOGYINPRACTICE.COM
Lauren Hurley / No 10 Downing Street CC BY-NC-ND 2.0
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
